Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · IEX Real-Time Price · USD
0.880
-0.052 (-5.54%)
At close: Jul 2, 2024, 4:00 PM
0.935
+0.055 (6.23%)
After-hours: Jul 2, 2024, 7:53 PM EDT
SONN Revenue
Sonnet BioTherapeutics Holdings had revenue of $92.73K in the twelve months ending March 31, 2024, down -53.29% year-over-year. In the fiscal year ending September 30, 2023, Sonnet BioTherapeutics Holdings had annual revenue of $147.81K, a decrease of -57.76%.
Revenue (ttm)
$92.73K
Revenue Growth
-53.29%
P/S Ratio
29.54
Revenue / Employee
$7,728
Employees
12
Market Cap
2.74M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 147.81K | -202.14K | -57.76% |
Sep 30, 2022 | 349.94K | -133.68K | -27.64% |
Sep 30, 2021 | 483.63K | - | - |
Sep 30, 2020 | 0 | - | - |
Sep 30, 2019 | 0 | - | - |
Dec 31, 2018 | 30.73M | -10.70M | -25.82% |
Dec 31, 2017 | 41.43M | -269.14K | -0.65% |
Dec 31, 2016 | 41.70M | 6.35M | 17.96% |
Dec 31, 2015 | 35.35M | 5.51M | 18.46% |
Dec 31, 2014 | 29.84M | 21.60M | 261.85% |
Dec 31, 2013 | 8.25M | 1.40M | 20.36% |
Dec 31, 2012 | 6.85M | 5.38M | 364.05% |
Dec 31, 2011 | 1.48M | 1.34M | 983.37% |
Dec 31, 2010 | 136.30K | -466.68K | -77.40% |
Dec 31, 2009 | 602.98K | 368.92K | 157.62% |
Dec 31, 2008 | 234.06K | -297.19K | -55.94% |
Dec 31, 2007 | 531.25K | 404.00K | 317.51% |
Dec 31, 2006 | 127.24K | 122.45K | 2,552.00% |
Dec 31, 2005 | 4.80K | - | - |
Dec 31, 2004 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Triangle | 27.47M |
Sintx Technologies | 2.78M |
Helius Medical Technologies | 668.00K |
60 Degrees Pharmaceuticals | 569.86K |
Exicure | 500.00K |
SONN News
- 5 weeks ago - Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting - GlobeNewsWire
- 6 weeks ago - Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Accesswire
- 7 weeks ago - Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update - Accesswire
- 2 months ago - Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference - Accesswire
- 3 months ago - Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting - Accesswire
- 4 months ago - Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective - Accesswire
- 4 months ago - Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers - Accesswire
- 4 months ago - Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update - Accesswire